RPbio Q1 2026 Earnings Show Growth
알피바이오
314140
Signal Score
Historical Avg Return (5d)
-0.18%
Data Coverage
100%n=3385
Risk-adjusted indicator based on 3385 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Q1 2026 Revenue: 35.13B KRW
- • Q1 2026 Operating Profit: 2.42B KRW
- • Q1 2026 Net Income: 2.62B KRW
- • Q1 2026 EPS: 302 KRW
- • Total Assets (Q1 2026): 164.69B KRW
AI Analysis Summary
RPbio Inc. reported strong financial results for Q1 2026, with revenue reaching 35.13B KRW, operating profit at 2.42B KRW, and net income at 2.62B KRW. This marks a significant turnaround from the negative operating and net income reported in 2024. The company's core business, manufacturing pharmaceuticals and health functional foods via OEM/ODM, continues to drive growth, particularly in the OTC soft capsule market where it holds over 60% share. Total assets increased to 164.69B KRW, and the capital procurement ratio improved to 5.26% from 8.22% at the end of 2025, indicating a healthier financial structure. The company maintains its market leadership through patented technologies like New Neosol and strong production capabilities. The positive performance suggests a favorable outlook, driven by increasing demand for health-related products and differentiated soft capsule formulations.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.